Phase 2 clinical trial data published in 2023 in the New England Journal of Medicine demonstrated that participants receiving the highest dose of retatrutide achieved a mean body weight reduction of approximately 24% over 48 weeks results that have generated considerable scientific interest
GLP-1: How It Works for Weight Loss GLP-1 belongs to the GLP-1 receptor agonist class of medications
If Singer and Brooks model is expanded to include cardiovascular disease without obesity or diabetes, the lives saved increases to 3.9m
Psychological wellbeing in patients on adequatedoses of lthyroxine: results of a large, controlled communitybased questionnaire study
In an animal model of AD, mesenchymal stem cell (MSC)-derived exosomes delivered intranasally reduced extracellular plaque, inflammation, and glial activation
Refined carbohydrates, phenotypic plasticity and the obesity epidemic